Drug Trial Radar · NCT03970837
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
Last checked: Nov 20, 2026Latest source record: Nov 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,764
Actual
Start
Jun 5, 2019
Primary completion
Oct 29, 2021
Study completion Jan 18, 2023
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Jun 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study \[contRAst 2 (201791: NCT03970837)\] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165 in combination with csDMARD(s), for the treatment of adult participants with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to csDMARD(s) or bDMARD(s). The study will consist of a screening phase of up to 6 weeks followed by a 52 week treatment phase in which participants will be randomized in a ratio of 6:6:3:1:1:1 to receive GSK3196165 150 milligrams (mg) subcutaneous (SC) weekly, GSK3196165 90 mg SC weekly, tofacitinib capsules (cap) 5 mg twice a day or placebo (three arms, each placebo arm will have 12 weeks placebo followed by 40 weeks active treatment) respectively, all in combination with csDMARD(s). Participants who, in investigator's judgement will benefit from extended treatment with GSK3196165 may be included in the long-term extension study \[contRAst X (209564: NCT04333147)\]. For those participants who do not continue into the long term-extension study, there will be an 8 week safety follow-up visit following the treatment phase.
Conditions
- Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab)Biological
GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.
TofacitinibDrug
Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.
PlaceboDrug
Placebo matching GSK3196165 and Tofacitinib was administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage (%) of Participants With 20% Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo (Global Cohort)Time frame: Week 12
- Percentage (%) of Participants With 20% Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 (Asia Cohort)Time frame: Week 12
Locations
269 sites in 18 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Flagstaff, Arizona
GSK Investigational Site
Glendale, Arizona
GSK Investigational Site
Mesa, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Poway, California
GSK Investigational Site
Riverside, California
GSK Investigational Site
Roseville, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Tustin, California
GSK Investigational Site
Van Nuys, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Fort Collins, Colorado
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
Boca Raton, Florida
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
Daytona Beach, Florida
GSK Investigational Site
Gainesville, Florida
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Margate, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
New Port Richey, Florida
GSK Investigational Site
Palmetto Bay, Florida
GSK Investigational Site
St. Petersburg, Florida
GSK Investigational Site
Tamarac, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Marietta, Georgia
GSK Investigational Site
Idaho Falls, Idaho
GSK Investigational Site
Evansville, Indiana
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Bowling Green, Kentucky
GSK Investigational Site
Lake Charles, Louisiana
GSK Investigational Site
Monroe, Louisiana
GSK Investigational Site
Hagerstown, Maryland
GSK Investigational Site
Worcester, Massachusetts
GSK Investigational Site
Grand Blanc, Michigan
GSK Investigational Site
Lansing, Michigan
GSK Investigational Site
Novi, Michigan
GSK Investigational Site
Freehold, New Jersey
GSK Investigational Site
Albuquerque, New Mexico
Showing 40 of 269 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.